Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
-
Title: “Assessment of the Pharmacokinetic and Safety of Otenaproxesul, a Non-Abusable, Novel, Anti-Inflammatory/Analgesic Compound”
Date:
Time:
Location:
“I’m delighted to present these results at the country’s premier gathering of pain specialists,” commented
The poster will be available in the
About
Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation therapies to target pain and inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307587198/en/
VP Investor Relations
+1 416-577-1443
christina@antibethera.com
Source: